Organic Acidemias

Definition And Pathophysiology

• Inborn errors of metabolism (IEM) affecting amino acids result from single-gene pathogenic variants causing enzyme or transporter defects.
• Individually rare but collectively common, with Phenylketonuria (PKU) having an incidence of 1:14,000 to 1:20,000.
• Two primary pathophysiological mechanisms drive these disorders:
  • Intoxication Type: Accumulation of proximal toxic metabolites, such as Leucine in Maple Syrup Urine Disease (MSUD) or Succinylacetone in Tyrosinemia.
  • Deficiency Type: Lack of essential downstream products, such as Melanin in Albinism or Neurotransmitters in PKU and BH4 deficiency.

Classification

Clinical Presentation

Acute Neonatal Intoxication

• Presents as a "sepsis-like" state following a symptom-free interval of 24–72 hours.
• Rapid deterioration marked by poor feeding, vomiting, lethargy, hypotonia, seizures, and coma.
• Specific features include encephalopathy with "boxing/bicycling" movements in MSUD, severe metabolic acidosis in organic acidemias, and pure hyperammonemia with respiratory alkalosis in UCDs.

Chronic Or Late-Onset Presentation

• Neurological: Intellectual disability (classic PKU, Homocystinuria), developmental regression, ataxia, and movement disorders.
• Hepatic: Liver failure, cirrhosis, and hepatocellular carcinoma seen in Tyrosinemia Type I.
• Ocular/Cutaneous: Ectopia lentis (Homocystinuria), cataracts (Galactosemia), and albinism.
• Psychiatric: Autism-like features and behavioral issues prevalent in untreated PKU.

Characteristic Odors

Key Prototype Disorders

• Phenylketonuria (PKU): Deficiency of Phenylalanine Hydroxylase (PAH) or BH4 cofactor. Results in severe intellectual disability, microcephaly, and hypopigmentation if untreated. Diagnosed via elevated Phenylalanine and low Tyrosine. Treated with low Phenylalanine diet and Sapropterin.
• Tyrosinemia Type I: Defect in Fumarylacetoacetate Hydrolase (FAH) causing accumulation of toxic succinylacetone. Presents with infantile liver failure and renal Fanconi syndrome. Treated with Nitisinone (NTBC) and specific diet.
• Maple Syrup Urine Disease (MSUD): Defect in Branched-chain $\alpha$-ketoacid dehydrogenase complex. Accumulation of Leucine, Isoleucine, and Valine. Presence of Alloisoleucine is pathognomonic.

Diagnostic Approach

First-Line Screening

• Blood Glucose: Detects hypoglycemia seen in MSUD and Tyrosinemia.
• Arterial Blood Gas (ABG): Differentiates metabolic acidosis (Organic acidemias) from respiratory alkalosis (UCDs).
• Plasma Ammonia: Critical to rule out Urea Cycle Disorders.
• Urine Ketones: Present in Organic Acidemias and MSUD; absent in Fatty Acid Oxidation Defects.

Confirmatory Investigations

• High Performance Liquid Chromatography (HPLC): Gold standard for quantifying plasma amino acids.
• Urine Organic Acids (GC-MS): Essential for identifying organic acidemias.
• Tandem Mass Spectrometry (TMS): Utilized for Newborn Screening on dried blood spots.
• Molecular Genetics: Gene panel testing or exome sequencing for definitive diagnosis.

Management Principles

Acute Decompensation

• Halt Protein Intake: Immediately suspend all exogenous protein sources.
• Reverse Catabolism: Administer high-calorie infusions (10% Glucose with Lipids) to suppress endogenous protein breakdown.
• Detoxification: Initiate hemodialysis for severe hyperammonemia or leucine toxicity. Utilize ammonia scavengers like Sodium Benzoate or Phenylacetate.
• Cofactor Administration: Provide empirical trials of Vitamin B12, Biotin, Thiamine, or Vitamin B6 depending on the suspected block.

Long-Term Management

• Dietary Modification: Implement lifelong restriction of the offending amino acid and supplement essential downstream products (e.g., Tyrosine in PKU).
• Surveillance: Regular monitoring of neurodevelopment, growth, and nutritional markers like Albumin, Zinc, and Selenium.
• Transplantation: Consider liver transplantation for MSUD, Tyrosinemia, and UCDs, or kidney transplantation for Methylmalonic Acidemia.